These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 10990271

  • 1. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.
    Cross EW, Park S, Perlin DS.
    Microb Drug Resist; 2000; 6(2):155-61. PubMed ID: 10990271
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals.
    Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, Williams M, Riley L, Chaturvedi V, Perlin DS.
    Clin Infect Dis; 2001 Sep 01; 33(5):E23-7. PubMed ID: 11477529
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G, Hof H, Mayser P, Mylonas I, Ruhnke M, Schaller M, Weissenbacher ER.
    Mycoses; 2015 Mar 01; 58 Suppl 1():1-15. PubMed ID: 25711406
    [Abstract] [Full Text] [Related]

  • 5. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.
    Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD.
    Antimicrob Agents Chemother; 2012 Mar 01; 56(3):1403-6. PubMed ID: 22232293
    [Abstract] [Full Text] [Related]

  • 6. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
    Wong-Beringera A, Hindler J, Brankovic L, Muehlbauer L, Steele-Moore L.
    Diagn Microbiol Infect Dis; 2001 Jan 01; 39(1):25-31. PubMed ID: 11173188
    [Abstract] [Full Text] [Related]

  • 7. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata.
    Defontaine A, Bouchara JP, Declerk P, Planchenault C, Chabasse D, Hallet JN.
    J Med Microbiol; 1999 Jul 01; 48(7):663-670. PubMed ID: 10403417
    [Abstract] [Full Text] [Related]

  • 8. Synergistic activity between Echinophora platyloba DC ethanolic extract and azole drugs against clinical isolates of Candida albicans from women suffering chronic recurrent vaginitis.
    Avijgan M, Mahboubi M, Moheb Nasab M, Ahmadi Nia E, Yousefi H.
    J Mycol Med; 2014 Jun 01; 24(2):112-6. PubMed ID: 24746726
    [Abstract] [Full Text] [Related]

  • 9. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
    Adjapong G, Hale M, Garrill A.
    Med Mycol; 2017 Aug 01; 55(6):686-689. PubMed ID: 27838642
    [Abstract] [Full Text] [Related]

  • 10. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
    Lynch ME, Sobel JD, Fidel PL.
    J Med Vet Mycol; 1996 Aug 01; 34(5):337-9. PubMed ID: 8912167
    [Abstract] [Full Text] [Related]

  • 11. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM, Reviákina V, Dolande M, Selgrad S.
    Med Mycol; 2009 Mar 01; 47(2):137-43. PubMed ID: 18651308
    [Abstract] [Full Text] [Related]

  • 12. Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic Candida.
    Kane A, Dinh H, Campbell L, Cain AK, Hibbs D, Carter D.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0012124. PubMed ID: 38695556
    [Abstract] [Full Text] [Related]

  • 13. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
    Hacioglu M, Guzel CB, Savage PB, Tan ASB.
    Med Mycol; 2019 Apr 01; 57(3):291-299. PubMed ID: 29846682
    [Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.
    Choukri F, Benderdouche M, Sednaoui P.
    J Mycol Med; 2014 Dec 01; 24(4):303-7. PubMed ID: 25442913
    [Abstract] [Full Text] [Related]

  • 15. [Azole resistance in Candida albicans].
    Perea S.
    Rev Esp Quimioter; 2000 Sep 01; 13(3):314-7. PubMed ID: 11086283
    [Abstract] [Full Text] [Related]

  • 16. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003.
    da Matta DA, de Almeida LP, Machado AM, Azevedo AC, Kusano EJ, Travassos NF, Salomão R, Colombo AL.
    Diagn Microbiol Infect Dis; 2007 Apr 01; 57(4):399-404. PubMed ID: 17240110
    [Abstract] [Full Text] [Related]

  • 17. Determining Susceptibility in Candida Vaginal Isolates.
    Sobel JD, Akins R.
    Antimicrob Agents Chemother; 2022 Jun 21; 66(6):e0236621. PubMed ID: 35604210
    [Abstract] [Full Text] [Related]

  • 18. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
    Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA.
    J Clin Microbiol; 2005 May 21; 43(5):2155-62. PubMed ID: 15872235
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.
    Lynch ME, Sobel JD.
    J Med Vet Mycol; 1994 May 21; 32(4):267-74. PubMed ID: 7983571
    [Abstract] [Full Text] [Related]

  • 20. In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.
    Damke E, Tsuzuki JK, Cortez DA, Ferreira IC, Bertoni TA, Batista MR, Donati L, Svidzinski TI, Consolaro ME.
    BMC Complement Altern Med; 2011 May 04; 11():35. PubMed ID: 21542936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.